HRP20160685T1 - Pripravci koji sadrže pneumokokne antigene - Google Patents
Pripravci koji sadrže pneumokokne antigene Download PDFInfo
- Publication number
- HRP20160685T1 HRP20160685T1 HRP20160685TT HRP20160685T HRP20160685T1 HR P20160685 T1 HRP20160685 T1 HR P20160685T1 HR P20160685T T HRP20160685T T HR P20160685TT HR P20160685 T HRP20160685 T HR P20160685T HR P20160685 T1 HRP20160685 T1 HR P20160685T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antigen
- acid sequence
- amino acid
- epitope
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 60
- 102000036639 antigens Human genes 0.000 title claims 60
- 108091007433 antigens Proteins 0.000 title claims 60
- 239000000203 mixture Substances 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 150000001413 amino acids Chemical class 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 150000001720 carbohydrates Chemical class 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 7
- 241000588650 Neisseria meningitidis Species 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 101100289918 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) lytB gene Proteins 0.000 claims 2
- 101100312899 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) ply gene Proteins 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 208000035109 Pneumococcal Infections Diseases 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000011814 protection agent Substances 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0714963.6A GB0714963D0 (en) | 2007-08-01 | 2007-08-01 | Compositions comprising antigens |
| US96686607P | 2007-08-29 | 2007-08-29 | |
| EP12197549.4A EP2572726B1 (en) | 2007-08-01 | 2008-08-01 | Compositions comprising pneumococcal antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160685T1 true HRP20160685T1 (hr) | 2016-07-15 |
Family
ID=38529101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160685TT HRP20160685T1 (hr) | 2007-08-01 | 2016-06-16 | Pripravci koji sadrže pneumokokne antigene |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20110243976A1 (enExample) |
| EP (2) | EP2197484A2 (enExample) |
| JP (2) | JP2010535025A (enExample) |
| CN (2) | CN104001165B (enExample) |
| AP (1) | AP2010005173A0 (enExample) |
| AU (1) | AU2008281438A1 (enExample) |
| BR (1) | BRPI0813892A2 (enExample) |
| CA (1) | CA2695169A1 (enExample) |
| CO (1) | CO6260103A2 (enExample) |
| CY (1) | CY1117689T1 (enExample) |
| DK (1) | DK2572726T3 (enExample) |
| EA (1) | EA018137B1 (enExample) |
| ES (1) | ES2580957T3 (enExample) |
| GB (1) | GB0714963D0 (enExample) |
| HR (1) | HRP20160685T1 (enExample) |
| HU (1) | HUE029670T2 (enExample) |
| PL (1) | PL2572726T3 (enExample) |
| PT (1) | PT2572726T (enExample) |
| SI (1) | SI2572726T1 (enExample) |
| WO (1) | WO2009016515A2 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US9486515B2 (en) | 2005-06-27 | 2016-11-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| EP2265634A2 (en) * | 2008-03-17 | 2010-12-29 | Intercell AG | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
| ATE523204T1 (de) * | 2009-02-16 | 2011-09-15 | Karlsruher Inst Technologie | Cd44v6-peptide als bakterielle infektionsinhibitoren |
| ES2531115T3 (es) | 2009-06-01 | 2015-03-10 | Novartis Ag | Combinaciones de clados de RrgB neumocócicos |
| WO2011008548A1 (en) | 2009-06-29 | 2011-01-20 | Genocea Biosciences, Inc. | Vaccines and compositions against streptococcus pneumoniae |
| CA2773637A1 (en) * | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| US9649372B2 (en) | 2009-12-22 | 2017-05-16 | Sanofi Pasteur Limited | Immunogenic compositions and related methods |
| EP2550289A4 (en) | 2010-03-12 | 2013-11-27 | Childrens Medical Center | NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| DK2590676T3 (en) | 2010-07-06 | 2016-10-24 | Glaxosmithkline Biologicals Sa | Virionlignende feed particles to self-replicating RNA molecules |
| JP5940064B2 (ja) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | 低用量のｒｎａを用いた大型哺乳動物の免疫化 |
| RS54489B1 (sr) | 2010-07-06 | 2016-06-30 | Glaxosmithkline Biologicals Sa | Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| PL3831406T3 (pl) | 2010-08-23 | 2024-09-09 | Wyeth Llc | Stabilne preparaty antygenów rLP2086 Neisseria meningitidis |
| BR112013004865A2 (pt) | 2010-08-31 | 2016-06-07 | Novartis Ag | lípidos adequados para entrega lipossomal de codificadores de proteínas rna |
| SMT202200311T1 (it) | 2010-08-31 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Liposomi pegilati per somministrare rna codificante un immunogene |
| RU2546873C2 (ru) * | 2010-09-10 | 2015-04-10 | УАЙТ ЭлЭлСи | Нелипидизированные варианты антигенов neisseria meningitidis orf2086 |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| MX344120B (es) | 2011-01-20 | 2016-12-06 | Genocea Biosciences Inc | Vacunas y composiciones contra streptococcus pneumoniae. |
| US9987354B2 (en) * | 2011-04-29 | 2018-06-05 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells |
| AU2012253359B2 (en) | 2011-05-11 | 2017-06-08 | Children's Medical Center Corporation | Multiple antigen presenting immunogenic composition, and methods and uses thereof |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US20140141070A1 (en) | 2011-07-06 | 2014-05-22 | Andrew Geall | Liposomes having useful n:p ratio for delivery of rna molecules |
| US20140255472A1 (en) | 2011-08-31 | 2014-09-11 | Andrew Geall | Pegylated liposomes for delivery of immunogen-encoding rna |
| DK3369742T3 (da) * | 2011-10-05 | 2020-10-19 | Univ Rockefeller | Dimere bakteriofaglysiner |
| US9493517B2 (en) * | 2011-11-07 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Conjugates comprising an antigen and a carrier molecule |
| EP2822586A1 (en) | 2012-03-07 | 2015-01-14 | Novartis AG | Adjuvanted formulations of streptococcus pneumoniae antigens |
| MY167723A (en) | 2012-03-09 | 2018-09-21 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| EP4056198A3 (en) | 2012-09-18 | 2022-12-07 | GlaxoSmithKline Biologicals SA | Outer membrane vesicles |
| KR20140075196A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CA2900008C (en) * | 2013-02-07 | 2025-10-07 | Children's Medical Center Corporation | PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| KR102255108B1 (ko) | 2013-03-08 | 2021-05-24 | 노파르티스 아게 | 활성제의 전달을 위한 지질 및 지질 조성물 |
| CN110251675A (zh) | 2013-05-03 | 2019-09-20 | 西莱克塔生物科技公司 | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 |
| EP4098276A1 (en) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3623361B1 (en) | 2013-12-19 | 2021-08-18 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| ES2908827T3 (es) | 2013-12-19 | 2022-05-04 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| WO2016037161A2 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| CN104844712B (zh) * | 2015-04-03 | 2019-06-28 | 长春百克生物科技股份公司 | 肺炎链球菌蛋白抗原及其制备方法和应用 |
| GB201509782D0 (en) * | 2015-06-05 | 2015-07-22 | Isis Innovation | Methods and products for fusion protein synthesis |
| CA3008042A1 (en) * | 2015-12-10 | 2017-06-15 | National Research Council Of Canada | Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| EP3600400A4 (en) | 2017-03-28 | 2021-01-13 | The Children's Medical Center Corporation | MULTIPLE ANTIGEN PRESENTATION SYSTEM (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGEN COMPOSITION AND THEIR USES |
| GB201705750D0 (en) | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | Peptide ligase and use therof |
| EP3634481A4 (en) | 2017-06-10 | 2021-07-21 | Inventprise, LLC. | MULTIVALENT CONJUGATE VACCINES WITH BIVALENT OR MULTIVALENT CONJUGATE POLYSACCHARIDES THAT CONFIRM ENHANCED IMMUNOGENICITY AND AVIDITY |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| CN111065417B (zh) | 2017-06-23 | 2024-04-19 | 美商艾芬尼维克斯公司 | 免疫原性组合物 |
| TW202019470A (zh) | 2018-09-12 | 2020-06-01 | 美商艾芬尼維克斯公司 | 多價肺炎球菌疫苗 |
| KR102922338B1 (ko) | 2018-09-12 | 2026-02-05 | 더 칠드런스 메디칼 센터 코포레이션 | 폐렴구균 융합 단백질 백신 |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| EP4010014A1 (en) * | 2019-08-05 | 2022-06-15 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| WO2021059181A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| EP4229208A4 (en) | 2020-10-14 | 2024-10-30 | George Mason Research Foundation, Inc. | METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023039223A1 (en) | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
| CN114507658B (zh) * | 2022-04-02 | 2022-07-05 | 深圳瑞德林生物技术有限公司 | 酶共表达系统及其在合成唾液酸的应用 |
| CA3256262A1 (en) * | 2022-06-07 | 2025-03-18 | Shanghai Alezyme Pharmaceuticals Ltd. | Fusion proteins including truncated forms of immunoglobulin A (IGA) protease and their uses |
| WO2024006863A1 (en) | 2022-06-30 | 2024-01-04 | Precision NanoSystems ULC | Lipid nanoparticle formulations for vaccines |
| CN116063548B (zh) * | 2022-07-08 | 2025-06-10 | 中国人民解放军陆军军医大学 | 一种融合蛋白KP-Ag1及其用作肺炎克雷伯菌疫苗抗原的应用 |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| CN117736279A (zh) * | 2023-04-21 | 2024-03-22 | 华中农业大学 | 胸膜肺炎放线杆菌的三个候选抗原及其应用 |
| WO2024259508A1 (pt) | 2023-06-22 | 2024-12-26 | Instituto Butantan | Antígeno multiepítopo, composição imunogênica compreendendo o referido antígeno, kit de diagnóstico do pneumococo, e usos do referido antígeno |
| AU2023457883A1 (en) | 2023-06-28 | 2025-12-18 | Global Life Sciences Solutions Canada Ulc | Lipid nanoparticle formulations for cell therapy and related methods |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
| WO2026033498A1 (en) | 2024-08-09 | 2026-02-12 | Genvax Technologies, Inc. | Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom |
| CN118702827B (zh) * | 2024-08-27 | 2025-03-07 | 南京澄实生物医药科技有限公司 | 一种预防肺炎链球菌感染的融合蛋白及其应用 |
Family Cites Families (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4315919A (en) * | 1980-10-06 | 1982-02-16 | Edward Shanbrom | Depyrogenation process |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| NZ230423A (en) | 1988-08-25 | 1993-08-26 | Liposome Co Inc | A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US6716432B1 (en) | 1988-12-16 | 2004-04-06 | James Cleland Paton | Pneumolysin mutants and pneumococcal vaccines made therefrom |
| DE68929323T2 (de) | 1988-12-16 | 2002-04-18 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin-mutanten und pneumokokken-impfstoffe daraus |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| ATE240401T1 (de) | 1989-03-21 | 2003-05-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| FI920131A0 (fi) | 1989-07-14 | 1992-01-13 | Praxis Biolog Inc | Cytokin- och hormonbaerare foer konjugatvaccin. |
| EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| ES2144414T3 (es) | 1990-12-20 | 2000-06-16 | Arch Dev Corp The University O | Control de la expresion de un gen por medio de una radiacion ionizante. |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| EP0582581B1 (en) | 1991-03-01 | 1999-05-06 | Minnesota Mining And Manufacturing Company | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES |
| AU663725B2 (en) | 1991-08-20 | 1995-10-19 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| ATE227979T1 (de) | 1993-04-22 | 2002-12-15 | Skyepharma Inc | Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| CZ288182B6 (en) | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DK0729351T3 (da) | 1993-11-16 | 2000-10-16 | Skyepharma Inc | Vesikler med reguleret afgivelse af aktivstoffer |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JP4303315B2 (ja) | 1994-05-09 | 2009-07-29 | オックスフォード バイオメディカ（ユーケー）リミテッド | 非交差性レトロウイルスベクター |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| US20020028215A1 (en) * | 1999-08-09 | 2002-03-07 | Jagath L. Kadurugamuwa | Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| PT942983E (pt) | 1996-10-31 | 2007-02-28 | Human Genome Sciences Inc | Antigénios e vacinas de streptococcus pneumoniae |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP0998557A2 (en) | 1997-07-21 | 2000-05-10 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| WO1999040936A2 (en) | 1998-02-12 | 1999-08-19 | American Cyanamid Company | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
| JP2002516251A (ja) | 1998-04-23 | 2002-06-04 | ユーエイビー リサーチ ファンデーション | 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法 |
| DK1075276T3 (da) | 1998-05-07 | 2008-02-11 | Corixa Corp | Adjuvanssammensætning og fremgangsmåder til dens anvendelse |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| JP2002521058A (ja) * | 1998-07-27 | 2002-07-16 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌由来の核酸及びタンパク質 |
| US20030134407A1 (en) * | 1998-07-27 | 2003-07-17 | Le Page Richard William Falla | Nucleic acids and proteins from Streptococcus pneumoniae |
| EP2053126A1 (en) | 1998-07-27 | 2009-04-29 | Sanofi Pasteur Limited | Streptococcus pneumoniae proteins and nucleic acid molecules |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| NZ509986A (en) | 1998-08-19 | 2003-10-31 | Baxter Healthcare S | Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines |
| DE122007000087I1 (de) | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
| AU1626199A (en) | 1998-12-04 | 2000-06-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vi-repa conjugate vaccine for immunization against salmonella typhi |
| DK1140157T3 (da) | 1998-12-21 | 2009-06-08 | Medimmune Inc | Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| KR100642044B1 (ko) | 1999-03-19 | 2006-11-10 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| EP1165795A2 (en) | 1999-03-26 | 2002-01-02 | Provalis UK Limited | Streptococcus pneumoniae antigens |
| EP1165796A2 (en) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| ATE325620T1 (de) | 1999-06-10 | 2006-06-15 | Medimmune Inc | Streptococcus pneumoniae proteine und impfstoffe |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
| BR0014285A (pt) | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico |
| PL355163A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| TR200200797T2 (tr) | 1999-09-25 | 2002-10-21 | University Of Iowa Research Foundation | İmmünostimülatör nükleik asitler |
| WO2001095935A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| JP2003530872A (ja) | 2000-04-27 | 2003-10-21 | メディミューン，インコーポレイテッド | 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物 |
| US20040091495A1 (en) | 2000-07-20 | 2004-05-13 | Lars Bjorck | Protein |
| ES2334641T3 (es) | 2000-09-01 | 2010-03-15 | Novartis Vaccines And Diagnostics, Inc. | Derivados aza heterociclicos y su uso terapeutico. |
| PL211125B1 (pl) | 2000-09-11 | 2012-04-30 | Novartis Vaccines & Diagnostic | Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
| EP1330473A2 (en) | 2000-10-26 | 2003-07-30 | Imperial College Innovations Limited | Streptococcal genes |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| AU2002347404A1 (en) | 2001-09-14 | 2003-04-01 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| KR100718371B1 (ko) | 2001-11-27 | 2007-05-14 | 애나디스 파마슈티칼스, 인코포레이티드 | ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도 |
| US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
| EP2275120A3 (en) | 2002-04-02 | 2011-06-08 | Ben-Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| US6743920B2 (en) | 2002-05-29 | 2004-06-01 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| CA2487831A1 (en) | 2002-06-11 | 2003-12-18 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| ATE477251T1 (de) | 2002-08-23 | 2010-08-15 | Novartis Vaccines & Diagnostic | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren |
| AU2003268353A1 (en) * | 2002-08-30 | 2004-03-19 | Tufts University | Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection |
| JP2006506989A (ja) | 2002-11-07 | 2006-03-02 | シナジー アメリカ，インコーポレイテッド | 肺炎球菌感染を治療または予防するための組成物および方法 |
| AU2003300021A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| US8193185B2 (en) | 2003-01-21 | 2012-06-05 | Novartis Vaccines And Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
| JP2007525157A (ja) * | 2003-04-15 | 2007-09-06 | インターツェル・アクチェンゲゼルシャフト | 肺炎連鎖球菌抗原 |
| RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| WO2005063283A1 (en) | 2003-12-31 | 2005-07-14 | Sungkyunkwan University | Vaccine comprising recombinant clpp protein of streptococcus pneumoniae |
| AU2005235080A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| WO2005097181A1 (en) | 2004-04-05 | 2005-10-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
| GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| WO2006084466A2 (en) * | 2005-02-11 | 2006-08-17 | Ace Biosciences A/S | Surface-located streptococcus pneumoniae polypeptides |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| CA2610667A1 (en) * | 2005-06-01 | 2006-12-07 | Variation Biotechnologies Inc. | Peptide-based influenza vaccine formulation |
| US9486515B2 (en) | 2005-06-27 | 2016-11-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| CN103251940A (zh) | 2005-12-22 | 2013-08-21 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2007116322A2 (en) | 2006-02-17 | 2007-10-18 | Novartis Ag | Purification of bacterial antigens |
| AU2007229449A1 (en) * | 2006-03-22 | 2007-10-04 | Novartis Ag | Regimens for immunisation with meningococcal conjugates |
| PT2086582E (pt) | 2006-10-12 | 2013-01-25 | Glaxosmithkline Biolog Sa | Vacina compreendendo uma emulsão adjuvante óleo em água |
| EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| US9493517B2 (en) * | 2011-11-07 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Conjugates comprising an antigen and a carrier molecule |
-
2007
- 2007-08-01 GB GBGB0714963.6A patent/GB0714963D0/en not_active Ceased
-
2008
- 2008-08-01 DK DK12197549.4T patent/DK2572726T3/en active
- 2008-08-01 SI SI200831646A patent/SI2572726T1/sl unknown
- 2008-08-01 EP EP08826694A patent/EP2197484A2/en not_active Withdrawn
- 2008-08-01 EP EP12197549.4A patent/EP2572726B1/en active Active
- 2008-08-01 CN CN201410192895.3A patent/CN104001165B/zh not_active Expired - Fee Related
- 2008-08-01 PL PL12197549.4T patent/PL2572726T3/pl unknown
- 2008-08-01 HU HUE12197549A patent/HUE029670T2/en unknown
- 2008-08-01 AP AP2010005173A patent/AP2010005173A0/en unknown
- 2008-08-01 AU AU2008281438A patent/AU2008281438A1/en not_active Abandoned
- 2008-08-01 WO PCT/IB2008/002866 patent/WO2009016515A2/en not_active Ceased
- 2008-08-01 PT PT121975494T patent/PT2572726T/pt unknown
- 2008-08-01 CA CA2695169A patent/CA2695169A1/en not_active Abandoned
- 2008-08-01 JP JP2010518777A patent/JP2010535025A/ja active Pending
- 2008-08-01 US US12/733,010 patent/US20110243976A1/en not_active Abandoned
- 2008-08-01 EA EA201070200A patent/EA018137B1/ru not_active IP Right Cessation
- 2008-08-01 CN CN200880108017A patent/CN101801409A/zh active Pending
- 2008-08-01 BR BRPI0813892A patent/BRPI0813892A2/pt not_active IP Right Cessation
- 2008-08-01 ES ES12197549.4T patent/ES2580957T3/es active Active
-
2010
- 2010-03-01 CO CO10023973A patent/CO6260103A2/es not_active Application Discontinuation
-
2013
- 2013-11-06 JP JP2013230378A patent/JP5838193B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-06 US US14/298,764 patent/US20140348868A1/en not_active Abandoned
-
2016
- 2016-06-16 HR HRP20160685TT patent/HRP20160685T1/hr unknown
- 2016-06-28 CY CY20161100580T patent/CY1117689T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104001165B (zh) | 2018-08-14 |
| EP2197484A2 (en) | 2010-06-23 |
| DK2572726T3 (en) | 2016-07-04 |
| EA018137B1 (ru) | 2013-05-30 |
| EP2572726B1 (en) | 2016-05-04 |
| PL2572726T3 (pl) | 2016-12-30 |
| US20110243976A1 (en) | 2011-10-06 |
| CY1117689T1 (el) | 2017-05-17 |
| WO2009016515A3 (en) | 2009-08-13 |
| JP2014034578A (ja) | 2014-02-24 |
| AP2010005173A0 (en) | 2010-02-28 |
| BRPI0813892A2 (pt) | 2017-05-09 |
| AU2008281438A1 (en) | 2009-02-05 |
| SI2572726T1 (sl) | 2016-08-31 |
| CO6260103A2 (es) | 2011-03-22 |
| GB0714963D0 (en) | 2007-09-12 |
| JP5838193B2 (ja) | 2016-01-06 |
| CA2695169A1 (en) | 2009-02-05 |
| EP2572726A1 (en) | 2013-03-27 |
| EA201070200A1 (ru) | 2010-08-30 |
| JP2010535025A (ja) | 2010-11-18 |
| PT2572726T (pt) | 2016-08-05 |
| US20140348868A1 (en) | 2014-11-27 |
| WO2009016515A2 (en) | 2009-02-05 |
| ES2580957T3 (es) | 2016-08-30 |
| CN104001165A (zh) | 2014-08-27 |
| HUE029670T2 (en) | 2017-03-28 |
| CN101801409A (zh) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160685T1 (hr) | Pripravci koji sadrže pneumokokne antigene | |
| JP2010535025A5 (enExample) | ||
| Girard et al. | A review of vaccine research and development: meningococcal disease | |
| RU2012116119A (ru) | Множественная вакцинация, включающая менингококки серогруппы с | |
| HRP20110685T1 (hr) | Cjepivo od konjugata pneumokoknog polisaharida | |
| DK2815762T3 (en) | Process for Conjugation of Bacterial Polysaccharides to Carrier Proteins | |
| ES2375704T3 (es) | Composición de vacuna multivalente. | |
| ES2240432T3 (es) | Conjugados polisacaridos de neumococo para uso vacuna contra el tetanos y la difteria. | |
| EA200901578A1 (ru) | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae | |
| HRP20221438T1 (hr) | Postupak glikokonjugiranja | |
| JP2020533438A5 (enExample) | ||
| JP2020533442A5 (enExample) | ||
| JP2020533437A5 (enExample) | ||
| HRP20100211T1 (hr) | Imunogeni pripravak | |
| WO2010141312A3 (en) | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same | |
| JP2004501873A5 (enExample) | ||
| JP2013079285A5 (enExample) | ||
| JP2014218516A5 (enExample) | ||
| US11325950B2 (en) | Immunogenic fusion protein | |
| RU2014122163A (ru) | Комбинации, включающие сахарид пневмококка серотипа 14 | |
| JP2012524099A5 (enExample) | ||
| GB2603362A (en) | Immunogenic compositions against enteric diseases and methods for its preparation thereof | |
| JPWO2019241672A5 (enExample) | ||
| Karma | Vaccination and otitis media | |
| Beuvery | Immunisation against bacterial meningitis |